TrialJCO precision oncology2025

Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial.

Sun Young Rha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.